ConvaTec Group PLC (CTEC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ConvaTec Group PLC (CTEC) has a cash flow conversion efficiency ratio of 0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX155.00 Million ≈ $18.86K USD) by net assets (GBX1.81 Billion ≈ $220.37K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ConvaTec Group PLC - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how ConvaTec Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ConvaTec Group PLC (CTEC) total liabilities for a breakdown of total debt and financial obligations.
ConvaTec Group PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ConvaTec Group PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
InkTec Co. Ltd
KQ:049550
|
-0.011x |
|
Tadmax Resources Berhad
KLSE:4022
|
-0.086x |
|
Indopoly Swakarsa Industry Tbk
JK:IPOL
|
0.051x |
|
Seowon
KO:021050
|
-0.015x |
|
LOOP INDUSTRIES DL-001
F:3L9
|
N/A |
|
Aton Resources Inc
V:AAN
|
0.128x |
|
Opticis Company Limited
KQ:109080
|
0.013x |
|
Nanoform Finland Plc
HE:NANOFH
|
-0.076x |
Annual Cash Flow Conversion Efficiency for ConvaTec Group PLC (2013–2024)
The table below shows the annual cash flow conversion efficiency of ConvaTec Group PLC from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see how much is ConvaTec Group PLC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX1.69 Billion ≈ $205.49K |
GBX396.20 Million ≈ $48.21K |
0.235x | +8.08% |
| 2023-12-31 | GBX1.69 Billion ≈ $205.95K |
GBX367.40 Million ≈ $44.70K |
0.217x | +24.03% |
| 2022-12-31 | GBX1.61 Billion ≈ $195.85K |
GBX281.70 Million ≈ $34.27K |
0.175x | -3.04% |
| 2021-12-31 | GBX1.69 Billion ≈ $206.21K |
GBX305.90 Million ≈ $37.22K |
0.180x | -24.52% |
| 2020-12-31 | GBX1.67 Billion ≈ $203.28K |
GBX399.50 Million ≈ $48.61K |
0.239x | -7.10% |
| 2019-12-31 | GBX1.56 Billion ≈ $189.93K |
GBX401.80 Million ≈ $48.89K |
0.257x | +18.26% |
| 2018-12-31 | GBX1.62 Billion ≈ $196.77K |
GBX352.00 Million ≈ $42.83K |
0.218x | +8.18% |
| 2017-12-31 | GBX1.52 Billion ≈ $185.40K |
GBX306.60 Million ≈ $37.30K |
0.201x | +234.77% |
| 2016-12-31 | GBX1.25 Billion ≈ $151.63K |
GBX74.90 Million ≈ $9.11K |
0.060x | +113.11% |
| 2015-12-31 | GBX-218.80 Million ≈ $-26.62K |
GBX100.30 Million ≈ $12.20K |
-0.458x | -576.75% |
| 2014-12-31 | GBX-2.17 Billion ≈ $-264.59K |
GBX147.30 Million ≈ $17.92K |
-0.068x | +36.95% |
| 2013-12-31 | GBX-2.13 Billion ≈ $-259.46K |
GBX229.10 Million ≈ $27.87K |
-0.107x | -- |
About ConvaTec Group PLC
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostom… Read more